Insulin Resistance presentations about Insulin Resistance EB with interest for Insulin Resistance Validating Insulin Resistance content Free registration form / enregistrement gratuit
1
2
  Français - August 16, 2011
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.

CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
  Topic  

Various

The understanding of Type 2 diabetes is very complex. Many factors must be considered when studying this disease. We are aware of all of the psychological, behavioural and genetic aspects... However, many elements are often unknown, but which should in fact be considered as important factors. In order avoid neglecting any aspect, all elements that have the potential of informing the public shall be found in this section.

Presentations listing

Why does nearly everyone regain weight after weight loss? - Prof. Joseph Proietto
How Can We Protect the Beta-Cell? - Prof. Michael Stumvoll
Could Glitazones Have Unique Properties in Early Diabetes... - Prof. Bernard Zinman
Keys To Optimal Diabetes Counseling - Dr. Diana L. Lawlor
Putting Evidence to Practice: Overview of a New Patient Tool - Dr. Diana L. Lawlor
American Diabetes Association 65th Scientific Sessions, San... - Prof. Timothy Davis
Acarbose in the Prevention of Cardiovascular Disease in... - Prof. Jean-Louis Chiasson
PROactive - Prof. Markolf Hanefeld
Where do we go from here? - Prof. Pierre Lefebvre
Obesity and Early Changes of Endothelial Dysfunction... - Dr. Helen Marcoyannopoulou Fojas
Statistical Models for Immediate Classification of... - Prof. John Öhrvik
Oxidative Stress: A Common Atherogenic Factor in IR, DM and... - Prof. Antonio Ceriello
Oxidative Stress and HDL Dysfunction in Metabolic Syndrome - Prof. John Chapman
Clofibrate Reduces Human Platelet Aggregation: A Possible... - Dr. Manish Khanolkar
The Endocannabinoid System: A New Therapeutic Target in... - Prof. Uberto Pagotto
Comparative Effects of Telmisartan and Losartan on Glucose... - Dr. Guiseppe Rosano
Postprandial Hyperglycemia and Hypertension Synergistically... - Dr. Thomas C. Wascher
Dysglycemia in Acute Coronary Syndrome Patients - Dr. Jacob Ilany
Nutrition - Prof. Andreas Pfeiffer
A Simple Tool to Predict the Risk of Cardiovascular Events... - Prof. Jaakko Tuomilehto
Control of Adipocyte Function by Nuclear Receptors of the... - Prof. Bart Staels
The Wheres and Whats of Body Fat Distribution - Prof. Steven Kahn
hiv
 Presentation 

"Why does nearly everyone regain weight after weight loss?"

Prof. Joseph Proietto (biography)
English - 2007-05-31 - 38 minutes
(46 slides)

Summary :
In this presentation Prof. Proietto discusses physiological adaptations that occur following weight loss that encourage re-gain of weight.

Interventions such as diet with or without physical activity, or even behaviour modification are not reliable methods for achieving substantial long-term weight loss. Only with surgery does this appear to be feasible. Why is this the case?
Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Peripheral signals influencing food intake
- Evidence in support of homeostatic regulation of weight (animal and human studies)
- Changes in the components of energy expenditure in relation to fat gain after overfeeding
- Evidence in support of weight being genetically determined
- Some gene mutations causing obesity
- Evidence in support of epigenetic change leading to obesity
- Some mechanisms promoting weight re-gain after weight loss

Bibliographic references :
1. Rudolph L. Leibel, M.D., Michael Rosenbaum, M.D., and Jules Hirsch, M.D.Changes in Energy Expenditure Resulting from Altered Body Weight N Engl J Med. 1995 Mar 9;332(10):621-8.

2. James A. Levine, Norman L. Eberhardt, Michael D. Jensen Role of Nonexercise Activity Thermogenesis in Resistance to Fat Gain in Humans Science. 1999 Jan 8;283(5399):212-4.

3. Adrian J Cameron, Timothy A Welborn, Paul Z Zimmet, David W Dunstan, Neville Owen, Jo Salmon, Marita Dalton, Damien Jolley and Jonathan E Shaw Overweight and obesity in Australia: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab) Med. J. Aust. 2003 May 5;178(9):427-32.

   


 Presentation 

"How Can We Protect the Beta-Cell?"

Prof. Michael Stumvoll (biography)
English - 2006-09-13 - 33 minutes
(22 slides)

Summary :
Not only the pathogenesis of type 2 diabetes but also disease progression is characterized by continuous decline of beta-cell function.Therefore, preservation of existing beta-cell function and protection from "toxic" processes is highly desirable for both prevention and chronic treatment. In principle, any lowering of prevailing glycaemia will protect the beta-cell by removing glucose toxicity....

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- The relationship between insulin sensitivity and beta cell function
- Agents that increase or preserve beta cell mass
- Preservation of beta cell function by rosiglitazone - possible mechanisms

   


 Presentation 

"Could Glitazones Have Unique Properties in Early Diabetes Therapy?"

Prof. Bernard Zinman (biography)
English - 2006-09-13 - 32 minutes
(32 slides)

Summary :
It is now well established that type 2 diabetes mellitus (T2DM) is a progressive disease characterized by beta-cell failure in the milieu of insulin resistance.The glitazones or thiazolidinediones (TZD) have been documented to have a robust effect on improving glucose control when used as monotherapy or in combination with other glucose lowering medications. In addition, accumulating evidence...

Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Guidelines for management of hyperglycaemia in T2DM.
- Mechanisms of action of glitazones.
- The ADOPT trial: study design, baseline characteristics of
participants including characteristics by GAD antibody
status.
- Outcome studies in IGT/IFG/T2DM.

   


 Presentation 

"Keys To Optimal Diabetes Counseling"

Dr. Diana L. Lawlor (biography)
English - 2005-10-21 - 22 minutes
(24 slides)

Summary :
For many people diabetes is like learning a new language, says Diana Lawlor, RN. It is then upto the diabetes educator to take the concepts of diabetes pathophysiology and management and apply knowledge translation.

Effective counseling involves a number of factors, such as understanding the principles of adult learning, knowledge of stages of change, life cycle knowledge and...

Learning objectives :
- Description of components considered by educators in assessing and working with patients to design effective diabetes management plans
- The educator's role in knowledge translation

   


 Presentation 

"Putting Evidence to Practice: Overview of a New Patient Tool"

Dr. Diana L. Lawlor (biography)
English - 2005-10-21 - 14 minutes
(9 slides)

Summary :
In this presentation Diana Lawlor, RN introduces a new educational tool designed to help diabetic patients understand diabetes, its pathophysiology, and how complications develop.

The tool focuses on enhancing an understanding of insulin resistance. It utilizes pictures to illustrate important points, and has a flow sheet that is helpful in operationalizing the CDA guidelines, and...

Learning objectives :
- Presentation of a new GSK-designed tool aimed at assisting in educating patients regarding insulin resistance

   


 Presentation 

"American Diabetes Association 65th Scientific Sessions, San Diego, June 9th-14th 2005: Selected Highlights"

Prof. Timothy Davis (biography)
English - 2005-06-17 - 46 minutes
(25 slides)

Summary :
In this presentation Prof. Davis covers several topics presented at the ADA's 65th Annual Scientific Sessions.

In a session on late-breaking clinical trials, data were presented on statin therapy in patients with diabetes in the TNT (Treating to New Targets) study, on the efficacy and safety of the PPAR alpha/gamma activator muraglitazar, and on the effects of rimonabant in mostly...

Learning objectives :
- Late-breaking clinical trials
- Update on newer therapies
- New data on chronic complications
- Type 1 vs type 2 diabetes
- Type 2 diabetes in youth
- Glucose intolerance in pregnancy
- Some topics of general interest

   


 Presentation 

"Acarbose in the Prevention of Cardiovascular Disease in Subjects with IGT and type 2 diabetes"

Prof. Jean-Louis Chiasson (biography)
English - 2005-04-16 - 28 minutes
(35 slides)

Summary :
The STOP-NIDDM Trial investigated the effect of acarbose on the incidence of type 2 diabetes and cardiovascular disease (CVD) in high risk subjects with IGT. Subjects with IGT (n = 1,429) were randomized to either placebo (n = 715) or acarbose (n = 714) 100 mg 3 times a day for a mean follow up time of 3.3 years. The study demonstrated that acarbose treatment resulted in a reduction of diabetes...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The rationale for the STOP-NIDDM Trial
• The goals of the STOP-NIDDM Trial
• The effect of acarbose treatment on the risk of progression to diabetes mellitus in patients with IGT
• The effect of acarbose treatment on the risk of cardiovascular events in patients with IGT
• The effect of acarbose treatment on the progression of carotid artery intima-media thickness in patients with IGT
• The effect of acarbose treatment on the risk of cardiovascular events in patients with type 2 diabetes mellitus

Bibliographic references :
The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999 Aug 21;354(9179):617-21.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002 Jun 15;359(9323):2072-7.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance: The STOP-NIDDM Trial JAMA 290:486-494. 2003.

Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004 May;35(5):1073-8.

Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M.Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004 Jan;25(1):10-6.

   


 Presentation 

"PROactive"

Prof. Markolf Hanefeld (biography)
English - 2005-04-16 - 33 minutes
(33 slides)

Summary :
Prof. Hanefeld presents the pleiotropic effects of pioglitazone such as on insulin sensitivity, glucose tolerance, lipid levels, HbA1c, etc. Of interest is the effect of pioglitazone on vascular function. Prof. Hanefeld discusses data supporting the positive effect of pioglitazone on coronary blood flow, atherosclerosis, plaque formation, smooth muscle cells, and left ventricular hypertrophy.
Learning objectives :
After viewing this presentation, participants will be able to discuss:
- The pleiotropic effects of pioglitazone;
- The PROactive study;
- Further secondary objectives of the proactive study.

Bibliographic references :
Bo Isomaa, Peter Almgren, Tiinamaija Tuomi, Björn Forsén, Kaj Lahti, Michael Nissén, Marja-Riitta Taskinen, and Leif Groop Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome Diabetes Care 24: 683-689

   


 Presentation 

"Where do we go from here?"

Prof. Pierre Lefebvre (biography)
English - 2005-04-16 - 33 minutes
(30 slides)

Summary :
Where do we go from here? Prof. Pierre Lefebvre begins his discourse of the future of “prediabetes”, diabetes, and metabolic syndrome research and action by reviewing exactly where here is and the International Diabetes Federation (IDF) and World Health Organization (WHO) projections for the next 20 to 25 years.

Do international organizations adequately recognize the scale of the...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The status of the diabetes epidemic in 2005
• The IDF/IDI and WHO projections for diabetes prevalence in the future
• Whether international organizations and the private sector adequately recognize the scale and scope of the problem
• The reactions of the IDF in response to the growing diabetes epidemic, including the World Diabetes Atlas and the Diabetes Action Now projects

Bibliographic references :
World Diabetes Atlas

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53.

   


 Presentation 

"Obesity and Early Changes of Endothelial Dysfunction Determined By Pulse Wave Velocity in Female Caucasian South Africans"

Dr. Helen Marcoyannopoulou Fojas (biography)
English - 2005-04-16 - 18 minutes
(19 slides)

Summary :
PURPOSE: To show that abnormal time of Pulse Wave Velocity associated with increased Body Mass Index (BMI) is an early indication of atherosclerosis.

METHOD: Pulse Wave Velocity was determined indirectly with the use of infrared sensors which picked up and recorded the left external carotid and left dorsalis pedis arteries simultaneously with a single lead ECG. The time delay...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

Data from a study of 115 Caucasian South African women on:
- The relationship between arterial wall elasticity and BMI

   


 Presentation 

"Statistical Models for Immediate Classification of Gluco-Metabolic State in Patients with Coronary Artery Disease"

Prof. John Öhrvik (biography)
English - 2005-04-16 - 26 minutes
(23 slides)

Summary :
OBJECTIVES: Abnormal glucose regulation (AbnGR) has serious prognostic implications in patients with coronary artery disease (CAD). This study tried to develop classification criteria, based on easily available clinical data, useful in acute CAD and to limit the number of oral glucose tolerance tests (OGTT) needed for accurate characterization.

METHODS: CAD patients were enrolled...

Learning objectives :
After viewing this presentation, participants will be able to discuss:

- Characterization of glucose metabolic state using ordinal logistic regression;
- Characterization of glucose metabolic state using single hidden layer back propagation neural network;
- The clinical implications of the proposed statistical model;
- The need for an OGTT immediately after a cardiovascular event.

Bibliographic references :
Malgorzata Bartnik, Lars Rydén, Roberto Ferrari, Klas Malmberg, Kalevi Pyörälä, Maarten Simoons, Eberhard Standl, Jordi Soler-Soler, John Öhrvik on behalf of the Euro Heart Survey Investigators The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: The Euro Heart Survey on diabetes and the heart Eur. Heart J., November 2004; 25: 1880 - 1890

   


 Presentation 

"Oxidative Stress: A Common Atherogenic Factor in IR, DM and CVD"

Prof. Antonio Ceriello (biography)
English - 2005-04-15 - 30 minutes
(23 slides)

Summary :
Type 2 diabetes is a worldwide increasing disease, resulting from the interaction between a subject's genetic makeup and lifestyle. In genetically predisposed subjects the combination of excess caloric intake and reduced physical activity induces a state of insulin resistance. When beta-cells are no more able to compensate for insulin resistance by adequately increasing insulin production,...

Learning objectives :
After viewing this presentation, participants will be able to discuss:

- The role of Glucose and fatty acid concentration on oxidative stress;
- Oxidative stress in smooth muscle, endothelial, and beta cells;
- The role of oxidative stress on post prandial hyperglycemia, diabetes, metabolic syndrome, and cardiovascular disease.

Bibliographic references :
T Inoguchi, P Li, F Umeda, HY Yu, M Kakimoto, M Imamura, T Aoki, T Etoh, T Hashimoto, M Naruse, H Sano, H Utsumi, and H Nawata High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells Diabetes 2000(49): 1939-1945.

Joseph L. Evans, Ira D. Goldfine, Betty A. Maddux, and Gerold M. Grodsky Are Oxidative Stress-Activated Signaling Pathways Mediators of Insulin Resistance and ß-Cell Dysfunction? Diabetes 2003 (52): 1-8.

Betty A. Maddux, Wendy See, John C. Lawrence, Jr., Amy L. Goldfine, Ira D. Goldfine, and Joseph L. Evans Protection Against Oxidative Stress—Induced Insulin Resistance in Rat L6 Muscle Cells by Micromolar Concentrations of -Lipoic Acid Diabetes 2001 (50): 404-410.

R. Marfella, G. Verrazzo, R. Acampora, C. La Marca, R. Giunta, C. Lucarelli, G. Paolisso, A. Ceriello, and D. Giugliano Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects Am J Physiol Endocrinol Metab, Jun 1995; 268: 1167 - 1173

Johannes Pleiner, Georg Schaller, Friedrich Mittermayer, Michaela Bayerle-Eder, Michael Roden, and Michael Wolzt FFA-Induced Endothelial Dysfunction Can Be Corrected by Vitamin C J. Clin. Endocrinol. Metab., Jun 2002; 87: 2913 - 2917.

Krauss S, Zhang CY, Scorrano L, Dalgaard LT, St-Pierre J, Grey ST, Lowell BB. Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction J Clin Invest. 2003 Dec;112(12):1831-42.

Antonio Ceriello and Enrico Motz Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited Arterioscler Thromb Vasc Biol 2004 24: 816 - 823

   


 Presentation 

"Oxidative Stress and HDL Dysfunction in Metabolic Syndrome"

Prof. John Chapman (biography)
English - 2005-04-15 - 31 minutes
(21 slides)

Summary :
An atherogenic disequilibrium of lipid metabolism is one of the key features of both the metabolic syndrome (MetS) and type 2 diabetes (DM2). Prof. John Chapman reviews here the disturbed lipid metabolism of the MetS and DM2 and discusses the mechanisms of lipid-induced vascular inflammation.

In particular, the antioxidative properties of HDL cholesterol are discussed along with...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The three intra-plaque processes involved in plaque rupture
• The five disequilibria that favour the progression of atherosclerosis
• The atherogenic lipid disequilibrium of the metabolic syndrome and type 2 diabetes
• The role of bioactive oxidized lipids in the induction of vascular wall inflammation
• The anti-atherogenic actions of HDL cholesterol
• The components of HDL that are implicated in its intrinsic antioxidative activity
• The usefulness of 8-isoprostanes as a global marker of systemic oxidative stress in the metabolic syndrome.

Bibliographic references :
Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1881-8.

Kontush A, de Faria EC, Chantepie S, Chapman MJ. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties. Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):526-33.

Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis. 2003 Nov;171(1):1-13.

Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, Kontush A. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004 Oct;89(10):4963-71.

Nobecourt E, Jacqueminet S, Hansel B, Chantepie S, Grimaldi A, Chapman MJ, Kontush A. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia. 2005 Mar;48(3):529-38

   


 Presentation 

"Clofibrate Reduces Human Platelet Aggregation: A Possible PPAR-α Mediated Effect"

Dr. Manish Khanolkar (biography)
English - 2005-04-15 - 24 minutes
(20 slides)

Summary :
Fibrates are PPARα agonists, increasingly used to treat a dyslipidemia characterized by elevated triglycerides and a low HDL-Cholesterol as is known to occur in individuals with the metabolic syndrome. Fibrates also appear to influence a number of emerging risk factors, including hemostatic and inflammatory markers, which may contribute to their cardioprotective effects. Platelet...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Platelet aggregation in atherothrombosis and type 2 diabetes;
- The expression of PPAR-alpha and PPAR-gamma in platelets;
- The effects of clofibrate and conjugated linoleic acid (CLA) on platelet aggregation;
- The role of PPAR-alpha in platelet aggregation;

Bibliographic references :
P. Ferroni, S. Basili, A. Falco and G. Davì Platelet activation in type 2 diabetes mellitus Journal of Thrombosis and Haemostasis Volume 2, Issue 8, Page 1282-1291, August 2004

Filiz Akbiyik, Denise M. Ray, Kelly F. Gettings, Neil Blumberg, Charles W. Francis, and Richard P. Phipps Human bone marrow megakaryocytes and platelets express PPAR , and PPAR agonists blunt platelet release of CD40 ligand and thromboxanes Blood, Sep 2004; 104: 1361 - 1368.

   


 Presentation 

"The Endocannabinoid System: A New Therapeutic Target in Metabolic Disorders"

Prof. Uberto Pagotto (biography)
English - 2005-04-15 - 25 minutes
(24 slides)

Summary :
Endocannabinoids and in particular anandamide and 2-arachidonoylglycerol are endogenous lipids capable of activating, the two cannabinoid (CB) receptors CB1 and CB2. These receptors belong to the G-protein-coupled family receptors and they were discovered in 1990s while investigating the molecular mode of action of the principal psychoactive component of Cannabis, r9-tetrahydrocannabinol, to...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The function and sites of action of the endocannabinoids
• Role of cannabanoid receptor type 1 (CB1) in the metabolic syndrome
• The potential benefit of CB1 blockade with agents such as rimonabant
• The mechanism of action of CB1 antagonists

Bibliographic references :
De Petrocellis L, Melck D, Bisogno T, Milone A, Di Marzo V. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience. 1999;92(1):377-87.

Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002 Jun;136(4):550-7.

Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol. 2001 Nov;134(6):1151-4.

Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. Nature. 2001 Apr 12;410(6830):822-5. Nature. 2001 Apr 12;410(6830):822-5.

Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003 Aug;112(3):423-31.

Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004 Apr;28(4):640-8.

Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 1998;63(8):PL113-7.

Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003 Apr;63(4):908-14.

Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes Relat Metab Disord. 2005 Feb;29(2):183-7.

   


 Presentation 

"Comparative Effects of Telmisartan and Losartan on Glucose Metabolism in Hypertensive Patients with Metabolic Syndrome"

Dr. Guiseppe Rosano (biography)
English - 2005-04-15 - 24 minutes
(14 slides)

Summary :
Angiotensin II receptor blockers (ARBs) are effective antihypertensives that reduce renal and cardiovascular complications in hypertensive diabetic patients and delay the onset of diabetes in non-diabetic hypertensives. Recent data have suggested that the ARB telmisartan may display PPAR gamma agonism and may improve glucose tolerance in animals. This 3-month study compared telmisartan (80...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- The benefits of angiotension receptor blockers in diabetes;
- A study comparing telmisartan and losartan on glucose metabolism and blood pressure in hypertensive patients with features of the metabolic syndrome.

Bibliographic references :
Stephen C. Benson, Harrihar A. Pershadsingh, Christopher I. Ho, Amar Chittiboyina, Prashant Desai, Michal Pravenec, Nianning Qi, Jiaming Wang, Mitchell A. Avery, and Theodore W. Kurtz Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR –Modulating Activity Hypertension, May 2004; 43: 993 - 1002.

   


 Presentation 

"Postprandial Hyperglycemia and Hypertension Synergistically Predict Multivessel CAD in Patients Undergoing Elective Coronary Angiography"

Dr. Thomas C. Wascher (biography)
English - 2005-04-15 - 17 minutes
(12 slides)

Summary :
Background and aims: In patients with coronary artery disease (CAD) undiagnosed disturbances of glucose metabolism mainly represent impaired glucose tolerance and postprandial diabetes (Wascher et al., Atherosclerosis 2004). Hypertension is an additional risk factor that is observed frequently in those patients. We aimed to investigate the impact of hypertension and postprandial...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- The relationship between postprandial hyperglycemia, hypertension and CAD in patients with angina undergoing elective coronary angiography.

   


 Presentation 

"Dysglycemia in Acute Coronary Syndrome Patients"

Dr. Jacob Ilany (biography)
English - 2005-04-15 - 32 minutes
(35 slides)

Summary :
In order to assess the frequency, characteristics and pathogenesis of glucose metabolism abnormalities in patients with acute coronary event, we performed OGTT to patients that were admitted to our intensive coronary unit. We included all patients with suspected coronary event without prior diagnosis of diabetes mellitus at age 20 to 80 years. Glucose, insulin and c-peptide level before and 120...

Learning objectives :
After viewing this presentation, participants will be able to discuss:

- The pathogenesis of dysglycemia
- Prevalence of dysglycemia
- The pathogenesis of the prediabetes condition
- The contribution of acute stress to dysglycemia

Bibliographic references :
Anna Norhammar, Åke Tenerz, Göran Nilsson, Anders Hamsten, Suad Efendíc, Lars Rydén and Klas MalmbergGlucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study The Lancet, Volume 359, Issue 9324, 22 June 2002, Pages 2140-2144

Frank B. Hu, Meir J. Stampfer, Steven M. Haffner, Caren G. Solomon, Walter C. Willett, and JoAnn E. MansonElevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes Diabetes Care 25: 1129-1134.

K. M. Choi, K. W. Lee, S. G. Kim, N. H. Kim, C. G. Park, H. S. Seo, D. J. Oh, D. S. Choi, and S. H. BaikInflammation, Insulin Resistance, and Glucose Intolerance in Acute Myocardial Infarction Patients without a Previous Diagnosis of Diabetes MellitusJ. Clin. Endocrinol. Metab., Jan 2005; 90: 175 - 180.

Åke Tenerz, Anna Norhammar, Angela Silveira, Anders Hamsten, Göran Nilsson, Lars Rydén, and Klas MalmbergDiabetes, Insulin Resistance, and the Metabolic Syndrome in Patients With Acute Myocardial Infarction Without Previously Known DiabetesDiabetes Care 26: 2770-2776.

M Tominaga, H Eguchi, H Manaka, K Igarashi, T Kato, and A SekikawaImpaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes StudyDiabetes Care 22: 920-924

J. Kuhl, A. Hilding, C. G. Östenson, V. Grill, S. Efendic and P. BåvenholmCharacterisation of subjects with early abnormalities of glucose tolerance in the Stockholm Diabetes Prevention Programme: the impact of sex and type 2 diabetes heredity Diabetologia: Volume 48, Number 1 pg 35-40

Markolf Hanefeld, Carsta Koehler, Katja Fuecker, Elena Henkel, Frank Schaper, and Theodora Temelkova-KurktschievInsulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study Diabetes Care 26: 868-874.

Andreas Festa, Ralph D’Agostino, Jr., Anthony J.G. Hanley, Andrew J. Karter, Mohammed F. Saad, and Steven M. HaffnerDifferences in Insulin Resistance in Nondiabetic Subjects With Isolated Impaired Glucose Tolerance or Isolated Impaired Fasting GlucoseDiabetes 53: 1549-1555.

Malgorzata Bartnik, Lars Rydén, Roberto Ferrari, Klas Malmberg, Kalevi Pyörälä, Maarten Simoons, Eberhard Standl, Jordi Soler-Soler, John Öhrvik on behalf of the Euro Heart Survey InvestigatorsThe prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: The Euro Heart Survey on diabetes and the heartEur. Heart J., November 2004; 25: 1880 - 1890.

   


 Presentation 

"Nutrition"

Prof. Andreas Pfeiffer (biography)
English - 2005-04-15 - 31 minutes
(41 slides)

Summary :
The effect of diet on cardiovascular risk has been known for some time. However, what is the effect of nutrition on the risk of diabetes and on the components of the metabolic syndrome?

Prof. Pfeiffer reviews the results of the EPIC-Potsdam Study and other studies, as he reveals the components of our diet that appear to both positively and negatively affect the components of the...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The benefit of diet in mediating cardiovascular risk
• The benefit of diet in mediating diabetes risk
• The beneficial effect of dietary modifications on fat metabolism
• The results of the EPIC-Potsdam Study

Bibliographic references :
Hu FB. Plant-based foods and prevention of cardiovascular disease: an overview. Am J Clin Nutr. 2003 Sep;78(3 Suppl):544S-551S.

Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, Manor O, Pella D, Berry EM. Lancet. 2002 Nov 9;360(9344):1455-61.

Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001 Sep 13;345(11):790-7.

Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50.

Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003 Mar;52(3):812-7.

Hofmann et al., Diabetologia 2005, in press.

Rochlitz H, Akpulat S, Bobbert T, Mai K, Mohlig M, Osterhoff M, Weickert MO, Pfeiffer AF, Spranger J. [Changes of biomarkers during weight reduction in metabolic syndrome.] Dtsch Med Wochenschr. 2005 Apr 29;130(17):1061-6. [Article in German]

Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004 Sep 22;292(12):1440-6.

McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PW, Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care. 2004 Feb;27(2):538-46.

Gannon MC, Nuttall FQ, Saeed A, Jordan K, Hoover H. An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. Am J Clin Nutr. 2003 Oct;78(4):734-41.

   


 Presentation 

"A Simple Tool to Predict the Risk of Cardiovascular Events in Patients with Diabetes Mellitus based on the Acarbose Meta-Analysis (MERIA)"

Prof. Jaakko Tuomilehto (biography)
English - 2005-04-15 - 23 minutes
(13 slides)

Summary :
OBJECTIVES: Different tools for the estimation of individual risk of cardiovascular diseases (CVD) in patients with diabetes mellitus (DM) exist. Our aim was to develop a risk score to predict the risk of CVD in patients with DM. In addition the score can estimate the risk reduction following acarbose treatment.

METHODS: The MERIA study showed that treatment with acarbose can...

Learning objectives :
After viewing this presentation, participants will be able to discuss:

- Data from the Acarbose meta analysis study (MERIA);
- Development of a multivariable Cox regression model to determine onset of cardiovascular disease;
- Data from the DECODE study (Diabetes Epidemiology : Collaborative analysis Of Diagnostic criteria in Europe)

Bibliographic references :
M. Hanefeld, M. Cagatay, T. Petrowitsch, D. Neuser, D. Petzinna, and M. Rupp Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies Eur. Heart J., January 2004; 25: 10 - 16.

   


 Presentation 

"Control of Adipocyte Function by Nuclear Receptors of the PPAR and REV-ERBalpha Family"

Prof. Bart Staels (biography)
English - 2005-04-14 - 34 minutes
(26 slides)

Summary :
Lipid and carbohydrate homeostasis is controlled by integrated systems that allow higher organisms to respond to metabolic changes. Numerous signals reciprocally convey information about body fat status from the periphery to the central nervous system in an attempt to maintain body weight stable throughout life. The role of the adipocyte in energy homeostasis goes beyond its function as a simple...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Rev-erbα- and PPARγ-mediated effects in vivo
- The effects of Rev-erbα deficiency in vivo

   


 Presentation 

"The Wheres and Whats of Body Fat Distribution"

Prof. Steven Kahn (biography)
English - 2003-10-31 - 48 minutes
(42 slides)

Summary :
Several factors contribute to insulin resistance, obesity being one of them. There are however some individuals who are lean and insulin resistant (1). These lean insulin resistant subjects were found to have more intra-abdominal fat compared to lean insulin-sensitive subjects, leading to the conclusion that intra-abdominal fat correlates with insulin resistance (1). Increasing intra-abdominal...

Learning objectives :
The participant will review the role of intra-abdominal obesity in insulin resistance, and new information on adiponectin.

Bibliographic references :
Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, Walden CE, Knopp RH, Kahn SE. «The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations : distinct metabolic effects of two fat compartments.» Diabetes. 2002 Apr;51(4):1005-15.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11916919&dopt=Abstract

2. Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD, Knopp RH, Kahn SE.«The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat.» Diabetes. 2003 Jan;52(1):172-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12502509&dopt=Abstract

3. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003 Apr;46(4):459-69. Epub 2003 Apr 10.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12687327&dopt=Abstract

   


  Login
  Username :
  Password :
   
  Lost your password?


  Search our website
  Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes.
 




MULTILEARNING - MULTIWEBCAST - MULTIEPOSTER - MULTIEPORTAL

Copyright © 2002-2015 MULTILEARNING Group INC.. All rights reserved.  Disclaimer
Powered by Multiwebcast - webcast services


USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.